Molecular approaches to antithrombotic therapy.
Several new approaches to direct and indirect inhibition of thrombin formation or activity promise to extend the benefits of pharmacologic antithrombotic interventions, both prophylactically and in acute therapy. Preliminary studies have found the new agents to be more specific and hemostatically safer than warfarin or heparin.
Scharfstein
J
J
Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston.
Loscalzo
J
J
D000590:Amino Acid Chloromethyl Ketones / Q000494:pharmacology; D000991:Antithrombins / Q000627:therapeutic use*; D001120:Arginine / Q000031:analogs & derivatives; D006493:Heparin / Q000494:pharmacology; D006629:Hirudins / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology; D010875:Pipecolic Acids / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology; D013449:Sulfonamides; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014859:Warfarin / Q000494:pharmacology
D000590:Amino Acid Chloromethyl Ketones; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D010875:Pipecolic Acids; D011480:Protease Inhibitors; D013449:Sulfonamides; C062510:hirugen; D014859:Warfarin; D006493:Heparin; D001120:Arginine; D013917:Thrombin; C031942:argatroban; C040308:phenylalanyl-prolyl-arginine-chloromethyl ketone